Guía de Práctica Clínica sobre Lupus Eritematoso Sistémico

555 Neumann I, Fuhrmann H, Fang I-F, Jaeger A, Bayer P, Kovarik J. Association between
mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune
disease on mycophenolate mofetil. Nephrol Dial Transplant 2008; 23: 3514–3520.
556 Liu L, Jiang Y, Wang L, Yao L, Li Z. Efficacy and Safety of Mycophenolate Mofetil
versus Cyclophosphamide for Induction Therapy of Lupus Nephritis. Drugs 2012; 72:
1521–1533.
557 Lertdumrongluk P, Somparn P, Kittanamongkolchai W, Traitanon O, Vadcharavivad S,
Avihingsanon Y. Pharmacokinetics of mycophenolic acid in severe lupus nephritis. Kidney
Int 2010; 78: 389–395.
558 Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake a WL, de Glas-Vos JW,
Bijl M et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative
lupus nephritis. A randomized controlled trial. Kidney Int 2006; 70: 732–742.
559 Wang S, Li X, Qu L, Wang R, Chen Y, Li Q et al. Tacrolimus versus cyclophosphamide as
treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized
prospective cohort study. Lupus 2012; 21: 1025–1035.
560 Yang M, Li M, He W, Wang B, Gu Y. Calcineurin inhibitors may be a reasonable
alternative to cyclophosphamide in the induction treatment of active lupus nephritis: A
systematic review and meta-analysis. Exp Ther Med 2014; 7: 1663–1670.
561 Moroni G, Gallelli B, Sinico RA, Romano G, Sinigaglia L, Messa P. Rituximab versus oral
cyclophosphamide for treatment of relapses of proliferative lupus nephritis: a clinical
observational study. Ann Rheum Dis 2012; 71: 1751–2.
562 Moroni G, Raffiotta F, Trezzi B, Giglio E, Mezzina N, Del Papa N et al. Rituximab vs
mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus
nephritis: a clinical observational study. Rheumatology 2014; 54.
doi:10.1093/rheumatology/ket462.
563 Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta M a. Rituximab in systemic lupus
erythematosus: A systematic review of off-label use in 188 cases. Lupus 2009; 18: 767–776.
564 Condon MB, Ashby D, Pepper RJ, Cook HT, Levy JB, Griffith M et al. Prospective
observational single-centre cohort study to evaluate the effectiveness of treating lupus
nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis
2013; 72: 1280–1286.
565 Mohan S, Radhakrishnan J. Geographical variation in the response of lupus nephritis to
mycophenolate mofetil induction therapy. Clin Nephrol 2011; 75: 233–241.
566 Wilson ECF, Jayne DRW, Dellow E, Fordham RJ. The cost-effectiveness of
mycophenolate mofetil as firstline therapy in active lupus nephritis. Rheumatology
(Oxford) 2007; 46: 1096–1101.
567 Kellum J a, Lameire N. Diagnosis, evaluation, and management of acute kidney injury: a
KDIGO summary (Part 1). Crit Care 2013; 17: 204.
GUÍA DE PRÁCTICA CLÍNICA SOBRE LUPUS ERITEMATOSO SISTÉMICO 477